Objective: to the pivotal interferon-␤-1b (IFN␤-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes. Here, we report the safety assessments.
spective study of patients with RRMS, where thyroid autoantibody levels and thyroid dysfunction did not differ significantly between baseline and IFN␤-1b treatment periods. 6 Though IFN␤-1b had a benign safety profile in the pivotal study, long-term data are necessary to determine safety and to exclude unexpected events, particularly those affecting mortality. The 16-Year Long-Term Follow-Up (LTF) was a cross-sectional, observational study that assessed outcomes (e.g., adverse events [AEs] and neutralizing antibodies [NAbs] ) over the long term in patients with relapsingremitting MS (RRMS) who participated in the pivotal IFN␤-1b study. 7, 8 METHODS Study design and procedures. LTF study was a multicenter, observational study, whose study design and procedures have been published. 9
Patients. A total of 372 patients with RRMS participated in the pivotal IFN␤-1b study conducted in 11 clinical centers in North America. 7, 8, 10 Between June 1988 and May 1990, patients were randomized to receive placebo (n ϭ 123), IFN␤-1b 50 g (n ϭ 125), or IFN␤-1b 250 g (n ϭ 124) SC every other day. 7, 10 After completion of the initial 2-year study, all patients were allowed to continue double-blind treatment and evaluations for an additional 3 years (up to 5 years in total). Upon approval of IFN␤-1b 250 g in 1993, placebo-treated and IFN␤-1b 50 gtreated patients were switched to the commercially available product (Betaseron ® ). All pivotal trial participants were eligible for the 16- Year LTF study, and all centers identified as many of their original participants as possible between January and November 2005.
Outcome variables. Year LTF study assessed the prevalence of AEs, including laboratory abnormalities, NAbs, and death. Patients were prompted via structured questionnaire to disclose relevant IFN␤-1b-induced AEs. In the pivotal and long-term follow-up studies, NAbs were measured by the viral cytopathic effect induction assay and confirmed by the myxovirus protein A assay. 11 Titers Ն20 NU/mL were considered NAb-positive.
Statistical analysis. For continuous data, mean, SD, and median are presented. Categorical data are described in frequency tables displaying counts and percentages. Laboratory and mortality data and AE incidence were evaluated for patients stratified according to treatment assignments in the original IFN␤-1b study. AE incidence was calculated for subgroups (e.g., centers with 100% ascertainment, patients using IFN␤-1b therapy over the 2 years prior to LTF visit, patients using IFN␤-1b 250 g for Ն80% of the time since initiation of the pivotal trial). Analysis of centers with 100% ascertainment obviated selection bias due to patient dropout. For some patients, the duration of MS therapies could not be ascertained accurately, so a conservative minimal exposure scenario was applied to define time on IFN␤-1b 250 g.
NAb titer at LTF was compared with NAb status during the pivotal study (e.g., maximum titer, titer at end of pivotal study). Clinical and MRI outcomes at LTF were compared for patients who were NAb-positive and NAb-negative during the pivotal study. Analyses were performed for the 250 g group, as well as for the pooled IFN␤-1b groups (50 g ϩ 250 g).
Proportions were compared using Fisher exact or McNemar tests. Depression at LTF was assessed using the European Quality of Life-5-Dimensional (EQ-5D) questionnaire. 12 MRI outcomes at LTF were compared with NAb-positive and NAbnegative patients during the pivotal study using nonparametric analysis of covariance with MRI T2 burden of disease (BOD) at pivotal trial baseline as a covariate.
Study protocol approvals, registrations, and patient consents. For the 16-Year LTF study (NCT00206635) , ethical approval was obtained from the centers' institutional review boards or independent ethical committees, and all participants or their proxy (i.e., legal representative or relative) provided written informed consent.
RESULTS Study population.
Demographic data for the original and LTF study populations are detailed elsewhere. 9 A total of 328 of the original 372 patients (88.2%) were identified. The numbers and proportions of patients identified were similar among placebo (109/123, 88.6%), IFN␤-1b 50 g (108/125, 86.4%), and IFN␤-1b 250 g groups (111/124, 89.5%). Of these, 293 (89%) were alive and 35 (11%) were deceased. A total of 260 patients (70% of original total, 79% of identified) agreed to participate in the LTF trial. This population included 7 deceased patients via proxy consent. Eight centers identified between 71% and 94% of their original patients. Three of 11 centers identified 100% of patients (n ϭ 80). Demographic characteristics of this subpopulation did not differ from those of all identified patients or those who consented to LTF (table 1) .
Seventy-four of the 260 participants (29%) had taken IFN␤-1b 250 g within 30 days of the LTF visit and 33% within the prior 2 years. Overall, IFN␤ discontinuation rates were high; some patients discontinued and restarted therapy over 16 years. Consolidating the 3 pivotal trial randomization groups, the median duration of exposure to IFN␤-1b was 7.9 years, constituting nearly 2,000 patient-years of IFN␤-1b 250 g therapy.
For the pooled treatment groups, 69 patients were using IFN␤-1b continuously in the 2 years prior to the LTF visit. Eighty-five patients had been on IFN␤-1b at some time in the last 2 years and 175 received no IFN␤-1b during the last 2 years. Other therapies used after the original IFN␤-1b study included prednisone, glatiramer acetate, IFN␤-1a, and mitoxantrone. The great number of therapy sequences renders individual analyses and commentary difficult, but some observed AEs are likely derived from treatment with other agents and not from IFN␤-1b.
AEs for patients continuously using IFN␤-1b in the 2 years prior to LTF. Patients receiving IFN␤-1b continuously in the 2 years prior to the LTF visit (n ϭ 69) experienced typical AEs: flu-like symptoms (31.9%), fever (21.7%), headache (27.5%), injection-site reactions (erythema, pain, or swelling, 81.2%), malaise (23.2%), myalgia (21.7%), or elevated liver transaminases (10.1%) (table 2). No skin necrosis was recorded. In the pivotal trial, IFN␤-1b increased the frequency of fever, malaise, and high transaminases. 7 Sixteen years later, 29% of patients were taking IFN␤-1b; the frequency of fever or malaise was the same in these patients as those not receiving IFN␤-1b at follow-up. However, 55% had received some MS therapy within 30 days before providing consent; therefore, fever and malaise could have been due to use of other drugs or chemotherapy. Only 3.4% of patients not receiving IFN␤-1b at follow-up had increased transaminases (table 2) .
Twenty-eight patients used the approved dose of IFN␤-1b for Ն80% over the 16 years (i.e., almost continuously since the beginning of the pivotal study). Within this continuously IFN␤-1b-treated group, the incidence of AEs was low.
Laboratory data at LTF. Laboratory measurements at LTF, including leukocyte counts, rheumatoid factor, and thyroid function, were similar across original treatment assignments (table e-1 on the Neurology ® Web site at www.neurology.org). Antithyroid peroxidase levels were 17 IU/mL for patients originally randomized to placebo, 21 IU/mL for the IFN␤-1b 50 g group, and 24 IU/mL for the IFN␤-1b 250 g group (normal is a titer of Ͻ50). Thyrotropin values were normal, ranging from 1.38 to 1.51 mIU/L (normal ϭ 0.4 to 4.0).
NAbs at LTF visit.
In subjects who received IFN␤-1b 50 g or IFN␤-1b 250 g, and who were NAbpositive at some time during the pivotal trial, NAb frequency and titer declined by the end of the trial. At some point during the pivotal trial, 52/124 (41.9%) patients prescribed IFN␤-1b 250 g had Table 1 Clinical and baseline characteristics at the start of the pivotal study, of all identified patients and of patients identified by centers with 100% patient identification, compared with all 16- titers Ն20 NU/mL, but by the end of the trial only 25/124 (20.2%) remained NAb-positive.
Of the 124 patients originally assigned to IFN␤-1b 250 g, 111 were identified at LTF and 80 had NAb data. Thirty-seven of 80 patients (46.3%) were NAb-positive at some point during the pivotal trial. At the end of the 5-year pivotal trial, 18 patients (22.5%) had titers Ն20 NU/mL; 8 (10.0%) had titers Ն100 NU/mL; 7 (8.8%) had titers Ն200 NU/ mL; and 6 (7.5%) had titers Ն400 NU/mL (these numbers are cumulative, so the number of patients with a titer Ն20 NU/mL includes those with titers Ն100 NU/mL, Ն200 NU/mL, and Ն400 NU/ mL). At LTF, only 9/80 (11.3%) patients originally assigned to IFN␤-1b 250 g were NAb-positive (figure 1). Thus, NAb frequency decreased by 76% compared with peak NAb frequency during the pivotal study. However, some of the 80 patients discontinued IFN␤-1b therapy. We recognize that NAb-positive patients who are doing well are more likely to remain on IFN␤-1b therapy, while NAbnegative patients who are doing poorly are more likely to cease IFN␤-1b treatment. To circumvent this potential source of bias, we analyzed a subgroup of patients (n ϭ 20) who were originally assigned to the IFN␤-1b 250 g group, who were treated continuously with IFN␤-1b during the last 2 years of LTF, and who had NAb data at LTF. During the pivotal trial, 6/20 (30.0%) of these patients were NAb-positive. By the end of the 5-year pivotal trial, 4/20 (20.0%) had titers Ն20 NU/mL. At LTF, 2/20 (10.0%) had titers Ն20 NU/mL. For patients randomized to IFN␤-1b 50 g or 250 g during the pivotal trial, who had received any IFN␤-1b during the 2 years prior to the LTF visit, and who provided NAb data at LTF, only 4/60 (6.7%) had a NAb titer Ն20 NU/mL, and 2 (3%) of these had a titer Ն400 NU/mL at LTF (figure 2). NAb positivity declined over time in patients treated with IFN␤-1b 50 g or 250 g during the pivotal trial. Similar trends were observed for patients treated continuously or during the 2 years prior to LTF visit with IFN␤-1b ( figure 2 ).
Mortality. At LTF, death occurred more frequently in patients originally assigned to placebo than to either of the IFN␤-1b treatments. Of those identified from the placebo group, 20/109 (18.3%) had died, compared with 9/108 (8.3%) in the IFN␤-1b 50 g group and 6/111 (5.4%) in the IFN␤-1b 250 g group. 9 Of the 15 patients in the IFN␤-1b treatment groups who died, 9 were NAb-negative and 6 were NAb-positive. The mean age at death of patients assigned to placebo was 49.9 years compared with 45.0 years for IFN␤-1b 50 g-treated and 45.3 years for IFN␤-1b 250 g-treated patients (table 3) . Causes of death were identified for 9 patients and included MS-related complications (n ϭ 2), cardiogenic shock, pneumonia-related complications, drowning, seizures, acetaminophen overdose, hepatic failure/pancreatic cancer, and lung cancer. The journal considers this Class III evidence because 1) it is conceivable that the placebo group could have made different choices in therapy or lifestyle, despite what appears to be roughly equivalent drug use after the randomized trial ended, and 2) analysis of the number of living patients shows a risk difference of 11.5% (95% CI 4 -19) .
Clinical and MRI outcomes at LTF visit vs NAb status
during pivotal study. When the IFN␤-1b 50 g and 250 g groups were pooled, NAb positivity was seen in 75 of 181 patients (41.4%) in the pivotal trial subset that was later evaluated in the LTF. High-titer NAb and confirmed NAb-positive subgroups were too small for reliable statistical analyses. In the subset who received IFN␤-1b 250 g in the pivotal trial, NAb positivity was observed in 44 of 96 patients (45.8%).
In Depression rates in patients who received IFN␤-1b for Ն80% of the time during the pivotal study were 25.0% and during the last 2 years of LTF were 32.1% ( p ϭ 0.53). Differences in depression rates at LTF between patients originally assigned to placebo relative to those initially randomized to IFN␤-1b were nonsignificant (table 2). MRI at 16 years was performed in 70% of patients in the original IFN␤-1b 250 g group. Differences between pivotal trial NAb-negative and NAb-positive groups at LTF were not significant for T2 BOD (median of 16,553 mm 2 in NAb-negative in pivotal trial vs 14,464 mm 2 in NAb-positive); T1 BOD (7,976 mm 2 vs 4,272 mm 2 ); normalized brain volume (72.2% vs 73.4%); and cervical cord crosssectional area (65.0 mm 2 vs 62.6 mm 2 ). DISCUSSION This LTF study identified 88.2% of patients enrolled in the original IFN␤-1b trial after 16 years with nearly 70% evaluated in detail. Some individuals did not consent to detailed assessment and were included only in survival analyses. The potential contribution of patients lost to follow-up or who declined participation was compared with patients who followed up regularly with investigating physicians. No differences were found in clinical status or AE frequencies during the pivotal trial between patients who did and did not participate in the LTF. These findings are consistent with an ongoing natural history study that has found no differences in demographic characteristics or clinical outcomes between patients who were easy or difficult to trace. 13 Physical examination and laboratory data were analyzed for evidence of safety issues associated with long-term IFN␤-1b use. One strength of this study was the ability to compare baseline and follow-up data for specific patients and patient subgroups. IFN␤-1b treatment-associated AEs decreased with time and were less frequent in the last 2 years of LTF compared with treatment during the pivotal trial. Frequency was low despite patients being prompted on the LTF questionnaire to remember all AEs. The slight increase in reported malaise may be attributable to disease progression. Routine autoinjector use, dose escalation at therapy initiation, and concomitant use of nonsteroidal anti-inflammatory drugsall introduced after the pivotal trial-have reduced treatment-associated AEs and increased IFN␤-1b tolerability. 14 These practices have likely contributed to the decline in AEs seen during LTF and in clinical trials initiated during the last 5 to 10 years. 15 Mild lymphopenia and elevated liver enzymes were detected in the pivotal trial, 7 but were seldom observed at LTF. No case of chronic liver disease was identified throughout 16 years of follow-up. Concerns that IFN␤-1b therapy increases the rate of autoimmune thyroid disease 4 were not supported by comparison of placebo and IFN␤-1b populations. Many of those patients originally assigned to placebo were ultimately treated with IFN␤-1b and other drugs. Though thyroid functions were normal in all groups at LTF (table 3) , subtle effects on the thyroid could have been missed at LTF because many patients eventually had high exposure to IFN␤ and other drugs. Lack of induction of thyroid function abnormalities and autoantibodies by IFN␤-1b is supported by other studies in RRMS 6 and SPMS. 5 NAbs to interferon occur with all IFN␤ products used to treat MS, but the clinical importance of NAbs remains controversial. [16] [17] [18] In the pivotal trial, NAb frequency was 41.9% during years 1 to 5 among patients receiving IFN␤-1b 250 g. While the incidence of NAbs had begun to decline by 5 years, 19 interim analysis of a small cohort of these patients (n ϭ 59) at 8 years revealed that 60% of NAb-positive patients reverted to NAb negativity. 20 Prevalence of NAb positivity was further reduced at 11.5 years, 21 and at 16 years, it was only 10% for those who had received IFN␤-1b in the pivotal trial and continuously during the 2 years before LTF. Among those patients, only 1 (1.5%) had a titer Ն100 NU/mL. In the larger cohort of LTF patients who received IFN␤-1b 250 g in the pivotal trial, 9/80 (11.3%) remained NAb-positive at LTF. The percentage of NAb-positive patients decreased over time in all treatment subgroups, although this decline was less pronounced among patients with the highest NAb titers (Ն400 NU/mL) during the pivotal study.
The mortality rate (18.3%) for patients from the placebo arm of the IFN␤-1b study was lower than expected based on natural history studies. For example, a follow-up study of 251 patients with MS demonstrated a mortality rate of 28% after 18.1 years. 22 Mortality rate was even lower in patients originally randomized to IFN␤-1b (6.8%, 15/219). To conclude that mortality is delayed in one assignment group over another, however, death rates will be reassessed for the entire cohort in a planned 20-year follow-up.
The depression rate in patients who received IFN␤-1b for Ն80% of the time at the LTF visit was 32.1%. This falls within the range of validated point prevalence rates for significant depression in the general MS population, which is between 27% and 54%. 23 Using the EQ-5D test, we found no evidence that depression was linked to IFN␤-1b.
A unique feature of this study was the identification of most patients from the North American pivotal IFN␤-1b study. The length of follow-up and the number of patient observation years were higher than in any other LTF study of an MS therapy, increasing the importance of our findings. Our data suggest that there are no high-frequency AEs associated with long-term IFN␤-1b therapy. However, patients' and doctors' views of efficacy-and possibly safety and AEs-likely played a role in drug choice and compliance. Patients continuing on long-term therapy are self-selected for positive outcomes, regardless of whether this outcome is due to nonaggressive disease or to treatment effects. Sources of bias in the LTF study and the analytical approaches undertaken to mitigate these biases are discussed in more detail elsewhere. 24 These study results support the long-term safety of IFN␤-1b therapy in MS. However, we acknowledge that our LTF sample, and those of other LTF studies, has a low statistical power to detect rare AEs. The long-term pharmacovigilance of patients enrolled in all experimental trials is thus encouraged.
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